Will innovation in oral therapies generate the next blockbusters in Immunology?

As the first TNF therapies go biosimilar, the next wave of innovation in Immunology is moving on, and not just in major indications like rheumatoid arthritis. New target pathways and oral therapies promise to impact patients, but what will be the biggest winner?

This Deep Dive includes:
  • Update on the top indications within Immunology
  • Analysis of the biggest movers and losers
  • Insights on acquisitions, drug approvals, and pipeline activity

Complete the form to download our Immunology Deep Dive. 


Have you seen our full list of 2016 Hot Indications? Click here to see this year's list.